Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The British Society for Rheumatology Biologics Register: 6 years on.

× No keyword cloud information.

18 in total

Review 1. Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.

Authors: Jamie Campbell; David Lowe; Matthew A Sleeman
Journal: Br J Pharmacol Date: 2011-04 Impact factor: 8.739

2. Methodological considerations when analysing and interpreting real-world data.

Authors: Til Stürmer; Tiansheng Wang; Yvonne M Golightly; Alex Keil; Jennifer L Lund; Michele Jonsson Funk
Journal: Rheumatology (Oxford) Date: 2020-01-01 Impact factor: 7.580

3. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

Authors: James B Galloway; Louise K Mercer; Alison Moseley; William G Dixon; Andrew P Ustianowski; Matthew Helbert; Kath D Watson; Mark Lunt; Kimme L Hyrich; Deborah Pm Symmons
Journal: Ann Rheum Dis Date: 2012-04-24 Impact factor: 19.103

4. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.

Authors: Louise K Mercer; Rebecca Davies; James B Galloway; Audrey Low; Mark Lunt; William G Dixon; Kath D Watson; Deborah P M Symmons; Kimme L Hyrich
Journal: Rheumatology (Oxford) Date: 2013-01 Impact factor: 7.580

5. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.

Authors: Kimme L Hyrich; Kath D Watson; Mark Lunt; Deborah P M Symmons
Journal: Rheumatology (Oxford) Date: 2010-07-29 Impact factor: 7.580

6. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Authors: Mark Lunt; Kath D Watson; William G Dixon; Deborah P M Symmons; Kimme L Hyrich
Journal: Arthritis Rheum Date: 2010-11

7. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

Authors: Rebecca Davies; James B Galloway; Kath D Watson; Mark Lunt; Deborah P M Symmons; Kimme L Hyrich
Journal: Ann Rheum Dis Date: 2011-07-22 Impact factor: 19.103

8. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

Authors: J B Galloway; K L Hyrich; L K Mercer; W G Dixon; A P Ustianowski; M Helbert; K D Watson; M Lunt; D P M Symmons
Journal: Ann Rheum Dis Date: 2011-07-21 Impact factor: 19.103

9. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.

Authors: Kimme L Hyrich; Chris Deighton; Kath D Watson; Deborah P M Symmons; Mark Lunt
Journal: Rheumatology (Oxford) Date: 2009-08-25 Impact factor: 7.580

10. Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.

Authors: Darren Plant; Ibrahim Ibrahim; Mark Lunt; Stephen Eyre; Edward Flynn; Kimme L Hyrich; Ann W Morgan; Anthony G Wilson; John D Isaacs; Anne Barton
Journal: Arthritis Res Ther Date: 2012-10-07 Impact factor: 5.156